Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lerociclib with Letrozole in Endometrial Carcinoma
NCT05712941Phase 3Withdrawn
- Sponsor
- EQRx
- Start
- Apr 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of lerociclib in endometrioid carcinoma, sponsored by EQRx. Planned start Apr 2023; status: withdrawn.
02
Drugs
lerociclib
03
Conditions
endometrioid carcinoma
Beyond the preview
Go deeper on NCT05712941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05712941.